Actualités

The UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

One of the largest global pharma companies would be created if a deal were to materialise.

BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.

European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.

A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times

The benchmark US stock measures were pointing higher before the opening bell Monday as President Don

Bristol Myers Squibb (BMY) just gave investors a strong quarter and a bigger outlook. Morgan Stanley read the same report and kept its rating exactly where it was. (The source of much of this article is a Morgan Stanley report shared with me.) Morgan Stanley sees the stock falling to $40, well ...

Find insight on AstraZeneca , Bristol Myers Squibb, Hartalega and more in the latest Market Talks covering health care.

Aug 3 (Reuters) - U.S. stock index futures edged higher on Monday as signs of de-escalating tensions in the Middle East weighed on crude prices, while investors prepared for another week packed with

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.

U.S. stocks were on track to extend Friday’s rally as President Trump said he had canceled planned strikes on Iran, adding that peace talks would resume Monday afternoon.

If maintained until close, the decline would be the stock’s biggest one-day percentage fall since the day of the 2024 U.S. presidential election.

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest

Aug 2 () - UK drugmaker AstraZeneca has been exploring a deal to combine with U. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report.

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company’s ties to the UK.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio. The company raised its full-year revenue and adjusted diluted earnings-per-share guidance, citing fir

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution

BMY highlights growth portfolio momentum, raises 2026 outlook and advances pipeline priorities as newer medicines drive results.

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Moby summary of Bristol-Myers Squibb Company's Q2 2026 earnings call

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

Strong revenue growth driven by Eliquis and key growth assets, offset by Opdivo decline and delayed readouts for Milvexian and Cobenfy.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter results that comfortably exceeded Wall Street expectations, driven by continued strength across its growth portfolio. The pharmaceutical company also raised its full-year 2026 financial outlook, sending its shares more than 1% higher in premarket trading on Thursday.